Skip to main content
. Author manuscript; available in PMC: 2021 Mar 18.
Published in final edited form as: Int J Pharm. 2020 Oct 26;591:119989. doi: 10.1016/j.ijpharm.2020.119989

Figure 3.

Figure 3.

Drug release and cellular interactions of aerosolizable nano-in-micro particles. Release assays of (A) LbL nanoparticles from micronized powders; (B) siRNA from micronized powders; (C) Percentage of Fine Particle Fraction (FPF %) of the micronized powders; (D) Effects of CHT-LbL siRNA microparticles on KRAS gene expression in tdTomato–expressing KP cell line (72 h); (E) Cell viability of tdTomato–expressing KP cell line in the presence of micronized powders; CLSM of td Tomato expressing KP cell line incubated with the LbL siRNA microparticles and 3D reconstruction after (F) 1 and (G) 12 h. Ch1 – DAPI, microparticles and proteins autofluorescence (λexc = 405 nm ; λemm = 461 nm); Ch2 – AF 488, siRNA (λexc = 473 nm ; λemm = 520 nm); Ch3 – Ds-Red2, tdTomato Kp cell line (λexc = 559 nm ; λemm = 581 nm). *P < 0.05; **P < 0.01; ***P < 0.001